Somogyi L, Szántó A, Polyák L, Baranyay F, Drinóczy M
Pécsi Orvostudományi Egyetem Urológiai Klinika, Budapest.
Orv Hetil. 1993 Aug 22;134(34):1851-6.
The net benefit of BCG immunotherapeutic prophylactic effect on recurrence of superficial bladder tumours was investigated. The BCG treatment group consisted of 121 stage Ta, T1 patients, while the control group, 49 patients, was treated only with transurethral resection. During 3-year follow-up recurrence rate in the control group was 55.1%, while in the BCG group in the two-and-a-half-year follow-up it was 23.9%. The yearly repeated 6-week cycles resulted in decrease of recurrence rate to 11.8%. The recurrence indexes were 2.2 and 0.6 in the control group and in the repeated treatment group respectively. A progression rate of 18.8% was recorded in the control group and 4.1% in the treatment group. Finally both clinical and investigative results were summarised and the necessity of repeated immunotherapeutic BCG courses were emphasized.
研究了卡介苗免疫治疗对浅表性膀胱肿瘤复发的预防作用的净效益。卡介苗治疗组由121例Ta期、T1期患者组成，而对照组49例患者仅接受经尿道切除术治疗。在3年的随访中，对照组的复发率为55.1%，而卡介苗组在两年半的随访中复发率为23.9%。每年重复6周的疗程使复发率降至11.8%。对照组和重复治疗组的复发指数分别为2.2和0.6。对照组的进展率为18.8%，治疗组为4.1%。最后总结了临床和研究结果，并强调了重复卡介苗免疫治疗疗程的必要性。
